Corvus Pharmaceuticals begins Phase 1b trial of soquelitinib for skin disease

September 30, 2026 4:05 PM

Corvus Pharmaceuticals (NASDAQ: CRVS) announced the start of enrollment in a Phase 1b clinical trial of soquelitinib for the treatment ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found